A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Trial Profile

A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Ipilimumab; Peginterferon alfa-2b
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KEYNOTE-029
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 02 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 22 Jan 2018 Results assessing safety and preliminary antitumor activity of pembrolizumab combined with either ipilimumab or PEG-IFN in patients with advanced melanoma or RCC, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top